Oblong’s Mezzanine Technology Is Changing the Way Companies Run Meetings

InfoComm 2018 put a heavy emphasis on user experience. This was easy to see with interactive games and technologies like drones, but the theme also applies to practical business solutions. No longer is it a luxury to have smart technology, it has become a necessity and Oblong Industries’ Mezzanine series of smart boards is designed to bring meetings and presentations to life, not only for those in the room but people brought in to the conference outside the office.

Paul Sprague, Director of Sales Engineering for Oblong Industries, was able to give MarketScale a walkthrough of the Mezzanine 600 last Thursday.

This content collaboration platform features six screens with video content integrated into the system. Able to accommodate ten devices for sharing into this space on multiple screens, the Mezzanine 600 is a powerful collaboration tool.

The user can move fluidly from board to board and display different windows as if the screens were one blank canvas. This allows for customization and presentation that traditional monitors or boards cannot achieve.

Sharing content via a gestural wand, companies can network with other walls and other locations, from Los Angeles to Chicago or anywhere in the world, and all the content is mirrored and shared to all locations simultaneously. This ability to meet and consume content remotely and in real time is transforming communication internationally.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More